We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+5.69%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$172M
AUM Growth
–
Cap. Flow
+$174M
Cap. Flow %
101.18%
Top 10 Hldgs %
90.24%
Holding
33
New
32
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$85.8M
2
AXDX
Accelerate Diagnostics
AXDX
+$44.2M
3
YTEN
Yield10 Bioscience, Inc. Common Stock
YTEN
+$7.58M
4
VRML
Vermillion, Inc.
VRML
+$4.24M
5
EQT icon
EQT Corp
EQT
+$3.59M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 86.63%
2 Energy 4.53%
3 Consumer Staples 2.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$91M 52.86%
+813,911
New +$85.8M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$39.6M 23.01%
+206,556
New +$44.2M
VRML
3
DELISTED
Vermillion, Inc.
VRML
$5.27M 3.06%
+2,717,514
New +$4.24M
YTEN
4
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$5.07M 2.94%
+221
New +$7.58M
EQT icon
5
EQT Corp
EQT
$31B
$3.13M 1.81%
+75,868
New +$3.59M
BIOL
6
DELISTED
Biolase, Inc.
BIOL
$3.12M 1.81%
+95
New +$2.97M
SWN
7
DELISTED
Southwestern Energy Company
SWN
$2.63M 1.53%
+96,483
New +$3.1M
MDVN
8
DELISTED
MEDIVATION, INC.
MDVN
$2.16M 1.25%
+43,360
New +$2.25M
GILD icon
9
Gilead Sciences
GILD
$167B
$1.76M 1.02%
+18,670
New +$1.93M
HNSN
10
DELISTED
HANSEN MEDICAL, INC. COM NEW
HNSN
$1.62M 0.94%
+292,093
New +$2.42M
ASPX
11
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$1.34M 0.78%
+25,500
New +$749K
CLR
12
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$1.25M 0.73%
+32,674
New +$1.61M
TRNX
13
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$1.25M 0.73%
+49,000
New +$1.25M
QDEL icon
14
QuidelOrtho
QDEL
$1.19B
$1.13M 0.65%
+38,975
New +$1.06M
ARAY icon
15
Accuray
ARAY
$30.8M
$1.08M 0.63%
+143,300
New +$1.01M
TTHI
16
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$1.03M 0.6%
+150,746
New +$974K
PTCT icon
17
PTC Therapeutics
PTCT
$6.52B
$1.03M 0.6%
+19,900
New +$876K
OVV icon
18
Ovintiv
OVV
$16.2B
$967K 0.56%
+13,940
New +$1.19M
MASI
19
DELISTED
Masimo
MASI
$964K 0.56%
+36,600
New +$903K
MRK icon
20
Merck
MRK
$315B
$852K 0.49%
+15,720
New +$876K
QTNT
21
DELISTED
Quotient Limited Ordinary Shares
QTNT
$715K 0.42%
+993
New +$472K
CELGZ
22
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$672K 0.39%
+213,432
New +$720K
CTRA
23
DELISTED
Coterra Energy
CTRA
$622K 0.36%
+21,000
New +$661K
OMED
24
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$489K 0.28%
+22,489
New +$461K
MACK
25
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$478K 0.28%
+5,376
New +$392K
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2014 Portfolio in Review

Q4 2014 is the first quarter with a 13F filing on record for Birchview Capital, which disclosed 33 positions worth $172M. Its ten largest holdings account for 90% of the portfolio.

Its largest position is Celgene Corp: 813,911 shares worth $91M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q4 2014 buy was Celgene Corp: 813,911 shares worth $91M.
  • Birchview Capital's ten largest holdings make up 90% of its $172M portfolio in Q4 2014.
  • Birchview Capital disclosed 33 positions in Q4 2014, its first 13F filing on record.

Based on Birchview Capital's 13F filing for Q4 2014, filed 6 Feb 2015.